meta-analysis
Dotaz
Zobrazit nápovědu
... in primary studies 263 -- Power analysis for meta-analysis 267 -- Power analysis for a test of homogeneity ... ... Example of psychometric meta-analysis 346 -- Comparison of artifact correction with meta-regression 348 ... ... 355 -- 40 WHEN DOES IT MAKE SENSE TO PERFORM A META-ANALYSIS? ... ... 359 -- How many studies are enough to carry out a meta-analysis? ... ... 369 -- 42 CUMULATIVE META-ANALYSIS 371 -- Introduction 371 -- Why perform a cumulative meta-analysis ...
First published xxviii, 421 stran : ilustrace ; 25 cm
- MeSH
- metaanalýza jako téma * MeSH
- statistika jako téma MeSH
- Publikační typ
- metaanalýza MeSH
- příručky MeSH
- Konspekt
- Statistika
- NLK Obory
- statistika, zdravotnická statistika
- MeSH
- interpretace statistických dat MeSH
- lidé MeSH
- sporty statistika a číselné údaje MeSH
- statistika jako téma metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- metaanalýza MeSH
Wiley series in probability and statistics
1st ed. xvii, 317 s.
Monographs in epidemiology and biostatistics ; vol. 31
2nd ed. x, 306 s.
- MeSH
- lékařství MeSH
- metaanalýza jako téma MeSH
- náklady a analýza nákladů MeSH
- Publikační typ
- metaanalýza MeSH
- Konspekt
- Lékařské vědy. Lékařství
- NLK Obory
- lékařství
- management, organizace a řízení zdravotnictví
Recently, concerns regarding the safety of red yeast rice (RYR) have been raised after the publication of some case reports claiming toxicity. Since the previous meta-analyses on the effects of RYR were mainly focused on its efficacy to improve lipid profile and other cardiovascular parameters, we carried out a meta-analysis on safety data derived from the available randomized controlled clinical trials (RCTs). Primary outcomes were musculoskeletal disorders (MuD). Secondary outcomes were non-musculoskeletal adverse events (Non-MuD) and serious adverse events (SAE). Subgroups analyses were carried out considering the intervention (RYR alone or in association with other nutraceutical compounds), monacolin K administered daily dose (≤3, 3.1-5 or >5 mg/day), follow-up (>12 or ≤12 weeks), with statin therapy or statin-intolerance and type of control treatment (placebo or statin treatment). Data were pooled from 53 RCTs comprising 112 treatment arms, which included 8535 subjects, with 4437 in the RYR arm and 4303 in the control one. Monacolin K administration was not associated with increased risk of MuD (odds ratio (OR) = 0.94, 95% confidence interval (CI) 0.53,1.65). Moreover, we showed reduced risk of Non-MuD (OR = 0.59, 95%CI 0.50, 0.69) and SAE (OR = 0.54, 95%CI 0.46, 0.64) vs. control. Subgroups analyses confirmed the high tolerability profile of RYR. Furthermore, increasing daily doses of monacolin K were negatively associated with increasing risk of Non-MuD (slope: -0.10; 95%CI: -0.17, -0.03; two-tailed p < 0.01). Based on our data, RYR use as lipid-lowering dietary supplement seems to be overall tolerable and safe in a large kind of moderately hypercolesterolaemic subjects.
Systematické přehledy se široce využívají jako prostředek medicíny založené na důkazech. Systematický přehled je metoda hledání, hodnocení a syntéza evidence. Meta-analýza znamená kvantitativní syntézu výsledků klinických pokusů nebo jiných primárních studií. Podáváme jednoduchý úvod do této metody, popisujeme dva příklady aplikace v medicíně, její přednosti a slabostí.
Systematic reviews are widely used in medicine as a method of decision making based on evidences. The systematic review is a method of locating and evaluation of a synthesising evidence. Meta-analysis refers to quantitative synthesis of the results of clinical trials or other primary studdis. Simple introductory account about meta-analysis is given. We describe two examples of meta-analysis application and strengths and weaknesses of this research method.
- MeSH
- finanční podpora výzkumu jako téma MeSH
- homeopatie MeSH
- lidé MeSH
- medicína založená na důkazech MeSH
- statistika jako téma MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- klinické zkoušky MeSH
- metaanalýza MeSH
- přehledy MeSH
- MeSH
- biliopankreatická diverze metody využití MeSH
- gastroplastika metody využití MeSH
- lidé MeSH
- obezita chirurgie terapie MeSH
- žaludeční balónek využití MeSH
- žaludeční bypass metody využití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- metaanalýza MeSH
- Geografické názvy
- Spojené státy americké MeSH
OBJECTIVE: To perform a network meta-analysis of randomised controlled trials of different surfactant treatment strategies for respiratory distress syndrome (RDS) to assess if a certain fraction of inspired oxygen (FiO2) is optimal for selective surfactant therapy. DESIGN: Systematic review and network meta-analysis using Bayesian analysis of randomised trials of prophylactic versus selective surfactant for RDS. SETTING: Cochrane Central Register of Controlled Trials, MEDLINE, Embase and Science Citation Index Expanded. PATIENTS: Randomised trials including infants under 32 weeks of gestational age. INTERVENTIONS: Intratracheal surfactant, irrespective of type or dose. MAIN OUTCOME MEASURES: Our primary outcome was neonatal mortality, compared between groups treated with selective surfactant therapy at different thresholds of FiO2. Secondary outcomes included respiratory morbidity and major complications of prematurity. RESULTS: Of 4643 identified references, 14 studies involving 5298 participants were included. We found no statistically significant differences between 30%, 40% and 50% FiO2 thresholds. A sensitivity analysis of infants treated in the era of high antenatal steroid use and nasal continuous positive airway pressure as initial mode of respiratory support showed no difference in mortality, RDS or intraventricular haemorrhage alone but suggested an increase in the combined outcome of major morbidities in the 60% threshold. CONCLUSION: Our results do not show a clear benefit of surfactant treatment at any threshold of FiO2. The 60% threshold was suggestive of increased morbidity. There was no advantage seen with prophylactic treatment. Randomised trials of different thresholds for surfactant delivery are urgently needed to guide clinicians and provide robust evidence. PROSPERO REGISTRATION NUMBER: CRD42020166620.
- MeSH
- Bayesova věta MeSH
- lidé MeSH
- novorozenec nedonošený MeSH
- novorozenec MeSH
- plicní surfaktanty * terapeutické užití MeSH
- povrchově aktivní látky MeSH
- síťová metaanalýza MeSH
- syndrom respirační tísně novorozenců * farmakoterapie prevence a kontrola MeSH
- těhotenství MeSH
- Check Tag
- lidé MeSH
- novorozenec MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- systematický přehled MeSH
